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were inversely correlated withMMRC dyspnea scale (r 0.492,
p¼0.007). Adjusted DLCO values showed negative correla-
tion with the grade of febrile neutropenia (r 0.612, p¼0.007).
The grade of cardiac toxicity showed negative correlation
with adjusted DLCO values (p¼0.006) and quadriceps
femoris muscle strength (p¼0.046). Respiratory and
quadriceps femoris muscle strength were positively
correlated with the number of steps per day (p¼0.011 and
p¼0.001 respectively). Performance status prior to HSCT
showed negative correlation with TRM (p¼0.05). In multiple
regression analysis; 24% of the variance in the daily average
METs was explained by MMRC (p¼0.07); 13% of the variance
in survival duration explained by quadriceps femoris
strength (p¼0.03); 54.6 % of the variance in cardiac toxicity
was explained by DLCO and quadriceps femoris strength
(p¼0.024).
Conclusions: Physical inactivity is a signiﬁcant problem in
HSCT recipients. Peripheral muscle strength and dyspnea are
signiﬁcant predictors of physical activity levels. Exercise
interventions to improve cardiorespiratory ﬁtness and
muscle strength may lead to beneﬁcial effects on transplant
outcomes in terms of the grade of cardiorespiratory
toxicities, febrile neutropenia and TRM.365
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Tuberculosis is caused by the pathogenic species of the
Mycobacterium tuberculosis complex. Following a primary
tuberculosis infection, adequate T-lymphocyte responses are
essential to preventing the progression of disease. Patients
with hematologic malignancies are at increased risk for
reactivation of latent tuberculosis infection (LTBI) due to
T-cell immunodeﬁciency caused by the disease itself or the
chemotherapy used as treatment. Incidence of tuberculosis
varies signiﬁcantly depending on country of birth and
underlying hematologic malignancy. The highest rate has
been identiﬁed among allogeneic hematopoietic stem cell
transplant (HSCT) patients, followed by patients with
non-Hodgkin lymphoma and patients with Hodgkin’s
lymphoma. Isoniazid (INH) therapy may be initiated in
patients found to have LTBI. INH therapy carries the risk of
adverse effects including hepatotoxicity and peripheral
neuropathy. INH induced hepatotoxicity occurs in 0.1-0.15%
of patients among the general population during preventa-
tive therapy. Data on the tolerability of INH in hematologic
malignancy patients receiving concomitant chemotherapy is
limited.
Primary objective: To investigate the incidence of LTBI in
patients with hematologic malignancies at UC San Diego
Health System.
Secondary objective: To investigate the safety and tolera-
bility of INH for treatment of latent tuberculosis in patients
with hematologic malignancies receiving chemotherapy.
This is a prospective, single center study using data
collected from an electronic patient database. Recruitment is
still on-going; we hope to enroll a total of 100 patients in this
study. All patients presenting with hematologic malig-
nancies at the Moores Cancer Center are screened for LTBI asa part of the standard of care using the QuantiFERON-TB
Gold Test (QFT-IT). A value of 0.35 IU/mL QFT-IT result is
considered positive. Patients with values of 0.35-1 IU/mLwill
be retested in 3-6 months to conﬁrm positivity. If patients
consent to participate, data collection will begin and
continued for 9 months if treatment for LTBI is initiated.
Data collected: age, gender, race, place of birth, cancer
diagnosis, transplant type/conditioning regimen, medication
list, PPD result history, history of LTBI and past treatment,
QFT-IT result, baseline renal function, liver function tests at
baseline and throughout therapy if INH was initiated.
Treatment decisions in the cases of a positive QFT-IT is at the
discretion of the treating physician. A descriptive analysis
including means, medians, ranges and proportions will be
calculated.366
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Introduction: Clostridium difﬁcile infection (CDI) is
considered the most common cause of acute infectious
diarrhea among hospitalized patients and is a major
concern in the hematopoietic stem cell transplantation
(HSCT) setting. HSCT patients constitute a highly vulner-
able population for CDI. This susceptibility can be
attributed to long hospitalizations, prolonged exposure to
of broad-spectrum antibiotics and chemotherapy-related
disruption of enteric mucosal barriers. With the increase of
CDI prevalence over the last decade the morbidity,
mortality, and medical care costs of CDI have reached
historic highs; therefore there is a need for prevention
policies that apply to the speciﬁc characteristics of this
population. An infection prevention surveillance audit at
the South Texas Veterans Health Care System Bone Marrow
Transplant Unit, during a 3 month period (October-
December 2013), revealed an increase in the rate of
healthcare associated hospital onset (HAHO) CDI (>72
hours after admission).
Methods:We assembled a multidisciplinary team with the
aim to decrease the rate of CDI over a 3 months period
(January-March 2014). A team including physicians,
nurses, pharmacists and infection preventionist was
called in to evaluate the rates of CDI and establish pro-
cedures to decrease these rates. Interventions included
the following: education of staff and patients about CDI
prevention and transmission, hand hygiene awareness,
proper use of cleaning products, de-cluttering of nurses'
work station, decontamination of common areas, daily
chlorhexidine baths, revision and review of the daily
cleaning of rooms, environmental service supervisor
visual room inspection and feedback after terminal
cleaning, use of ultraviolet pulses of light (UVC pulsed
technology), restriction of CDI positive patients to their
room and contact precautions until 48 hours after
resolution of diarrhea stools.
Results: Visual inspection of the roomwas increased to 100%,
as rooms were not released until a sign was placed on the
door signed by the environmental service supervisor
performing the inspection. Usage of the UVC units increased
from 17.5 per month (pre-intervention) on average to 42 per
month (post intervention). Hand hygiene was 100% based on
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from a cumulative of 73 per 10.000 patient-days to a rate of
23.8 per 10.000 patient-days, with no new cases during the
last month of surveillance.
Conclusion: A multidisciplinary approach to decrease rates
of CDI including: education, enhanced environmental
cleaning with review and feedback, and standard use of UVC
pulsed technology was effective to reduce the rates of CDI in
a bone marrow transplant unit.367
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Growth factors are routinely used after autologous
transplantation to shorten the duration of neutropenia.
Tbo-ﬁlgrastim (TBO) was recently approved in the U.S. for
patients with non-myeloid malignancies. The Average
Wholesale Price for TBO is 20% less than Filgrastim (FGS).
Whether TBO is comparable to FGS for reducing time to
engraftment following HSCT is unknown. A cost-savings
initiativewas undertaken at NorthwesternMemorial Hospital
to substitute TBO for FGS in all autografts. Herein are the re-
sults of an observational study which compares TBO and FGS.
FGS patients were treated from10/2013-4/14/2014 and TBO
patients between 4/15/14-9/20/2014. All patients were
treated for multiple myeloma with melphalan 200mg/m2.
TBO and FGS were initiated day+5 after stem cell infusion,
and discontinued the ﬁrst day the absolute neutrophil
exceeded 1000/ml. Time to engraftment was deﬁned as
the number of days from stem cell re-infusion until the
ﬁrst day the ANC exceeded 500cell/ml. TBO and FGS dose
was rounded as follows: <80kg received 300mcg/day,
>80mg<120kg received 480mcg and those >120kg received
600mcg/day.
96consecutively treatedpatientswere included-48 treated
with TBO and 48 treated with FGS. No signiﬁcant differenceTable 1
Filgrastim versus TBO-ﬁlgrastim
Characteristic (median/range) Filgrastim TBO-Filgastim P-value
Number 48 48
Age 57(42-69) 59(38-69) 0.9299
Gender (male/%) 27(56) 30(52) 0.8395
Weight (kg) 76(47-120) 84(50-160) 0.1227
Body surface area (adjusted) 1.8(1.45-2.2) 1.8(1.45-2.25) 0.8755
Melphalan dose (mg) 365(290-440) 365(290-45) 0.99
G-CSF dose(mcg/kg) 389(300-600) 413(300-600) 0.2584
Number of CD34 stem cell
infused
(million/kg) 6.57(2.97-20.9) 7.04(3.6-19.1) 0.4621
Documented infection (%) 6(12.5) 3(6) 0.468
Febrile neutropenia (%) 27(56) 20(41) 0.2204
Time to engraftment (days) 12(9-23) 13 (10-26) 0.0338
Engraftment > 14days (%) 8(17) 16(33) 0.0521
Total number of G-CSF doses
(mean/days)
9.42(6-24) 9.8(5-24) 0.5109
Length of stay(days) 16(13-51) 16(12-27) 0.4118
Elevated temps(>100.5) for
> 48 hours
9(19) 5(10) 0.3864
Hospital mortality 0 1 0.99was observed for diagnosis, age, gender, weight, BSA, growth
factor dose or dose/kg, number of stem cells infused, number
of patients who developed febrile neutropenia or micro-
biologically proven infection or prolonged fever (>48 hours).
Median time to engraftment and delayed engraftment
(>14days) was signiﬁcantly longer in the TBO-treated
patients. There was no difference in overall length of stay or
hospital mortality.
TBO-ﬁlgastrim appears to be effective in reducing the time
of neutropenia and stem cell engraftment. However delayed
engraftment, especially as observed >14 days after stem cell
infusion,was observed signiﬁcantlymore often inTBO treated
patients compared to those treated with FGS. These results
require conﬁrmation through a large randomized trial.368
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Allogeneic hematopoietic stem cell transplantation is being
employed as a life-saving procedure for greater numbers of
patients each year. Outpatient, reduced intensity transplants
and haplo-matched transplants, recognition of limited efﬁ-
cacy for chemotherapy in high risk diseases, and extending
the age limit for adults have all contributed to the growing
numbers. As a consequence, the demand for donor screening
resources has also increased. The National Marrow Donor
Programs (NMDP) has published the Assessment Tool at
Workup that has been recommended for use in determining
eligibility of unrelated donors. In order to avoid the risk of
bias in determining eligibility of related donors, the same
criteria are being applied to them at many centers. As a
referral center for complex transplants and increasing
numbers of donors, we reviewed the outcomes of related
donor screening and need for “additional” testing.
All donors were evaluated through a nurse practitioner-
based clinic with physician backup. All donors were
evaluated for bone marrow as well as peripheral blood
donation regardless of the requested product. Sixty-two
related potential donors were screened at MSKCC from
February through September 2014. The median age was
48yrs and they were equally divided between males and
females. Their demographics and outcomes are described in
Table 1. Based on initial routine screening studies and
utilizing the NMDP guidelines 15 donors (24%) were deemed
eligible and cleared for donation; 6 were ineligible according
to the NMDP guidelines for the following diagnoses: sickle
cell trait, systemic lupus, multiple sclerosis, history of
cervical cancer, babesiosis, and brain arteriovenous
malformation. Forty-seven (76%) donors did not clear
initially and 45 required additional evaluation based on  1
abnormalities (Table 2). These may have included laboratory
or imaging studies, informal or formal subspecialty
consultation or “other studies” such as bone marrow
procedure. Notably only 1/14 foreign born donors cleared
following initial evaluation. Forty-four (71%) donors actually
donated, 4 of whom were deemed ineligible but were used.
In all but 13 cases, the additional testing led to clearance.
